Miura Toshiyuki, Kimura Mikio, Koibuchi Tomohiko, Endo Tokiomi, Nakamura Hitomi, Odawara Takashi, Wataya Yusuke, Nakamura Tetsuya, Iwamoto Aikichi
Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Am J Trop Med Hyg. 2005 Sep;73(3):599-603.
Imported malaria remains an important problem in Japan. We have reviewed the medical records of 170 cases of malaria in our hospital, which corresponds to 14.9% of the total cases in Japan. The predominant malarial species was Plasmodium falciparum (52.3%), and the most frequent area of acquisition was Africa (54.2%), followed by Asia (20.9%) and Oceania (19.6%). The most common reason for travel among Japanese patients was business. A significant proportion (22.2%) of vivax malaria cases experienced relapse despite standard primaquine therapy. Most primaquine failures were from Oceania. We also found that a substantial number of Japanese patients contracted malaria without chemoprophylaxis and consulted medical facilities with an unfavorably long delay from initial symptoms (median: 3.0 days). Direct education of travelers and travel companies, in addition to health care providers, is likely necessary to improve outcomes of imported malaria.
输入性疟疾在日本仍然是一个重要问题。我们回顾了我院170例疟疾患者的病历,这占日本疟疾病例总数的14.9%。主要疟原虫种类为恶性疟原虫(52.3%),最常见的感染地区是非洲(54.2%),其次是亚洲(20.9%)和大洋洲(19.6%)。日本患者出行的最常见原因是商务。尽管采用了标准的伯氨喹治疗,但仍有相当比例(22.2%)的间日疟病例复发。大多数伯氨喹治疗失败的病例来自大洋洲。我们还发现,大量日本患者在未进行化学预防的情况下感染疟疾,且从出现初始症状到咨询医疗机构的延迟时间很长(中位数:3.0天)。除了医疗保健提供者外,对旅行者和旅游公司进行直接教育可能对于改善输入性疟疾的治疗效果是必要的。